114 related articles for article (PubMed ID: 37926864)
1. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer.
Chen YF; Pang YC; Wang HC; Wu PE; Chen ZJ; Huang D; Peng DL; Yan YM; Liu C; Wu LC; Fan XZ; Cheng YX; Liu YQ
Br J Pharmacol; 2024 Apr; 181(8):1221-1237. PubMed ID: 37926864
[TBL] [Abstract][Full Text] [Related]
2. Centipeda minima extract sensitizes lung cancer cells to DNA-crosslinking agents via targeting Fanconi anemia pathway.
Fan XZ; Chen YF; Zhang SB; He DH; Wei SF; Wang Q; Pan HF; Liu YQ
Phytomedicine; 2021 Oct; 91():153689. PubMed ID: 34446320
[TBL] [Abstract][Full Text] [Related]
3. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.
Shen C; Oswald D; Phelps D; Cam H; Pelloski CE; Pang Q; Houghton PJ
Cancer Res; 2013 Jun; 73(11):3393-401. PubMed ID: 23633493
[TBL] [Abstract][Full Text] [Related]
4. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Jacquemont C; Taniguchi T
Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
[TBL] [Abstract][Full Text] [Related]
5. mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells.
Guo F; Li J; Du W; Zhang S; O'Connor M; Thomas G; Kozma S; Zingarelli B; Pang Q; Zheng Y
Leukemia; 2013 Oct; 27(10):2040-2046. PubMed ID: 23538752
[TBL] [Abstract][Full Text] [Related]
6. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
8. Caffeine Has a Synergistic Anticancer Effect with Cisplatin via Inhibiting Fanconi Anemia Group D2 Protein Monoubiquitination in Hepatocellular Carcinoma Cells.
Oda Y; Hidaka M; Suzuki A
Biol Pharm Bull; 2017 Nov; 40(11):2005-2009. PubMed ID: 28855448
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of
Komatsu H; Masuda T; Iguchi T; Nambara S; Sato K; Hu Q; Hirata H; Ito S; Eguchi H; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
Anticancer Res; 2017 Mar; 37(3):1083-1090. PubMed ID: 28314268
[TBL] [Abstract][Full Text] [Related]
10. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
11. mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.
Wang CI; Chen YY; Wang CL; Yu JS; Chang YS; Yu CJ
Oncotarget; 2016 May; 7(18):25432-42. PubMed ID: 27009856
[TBL] [Abstract][Full Text] [Related]
12. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition.
Jin HO; Hong SE; Woo SH; Lee JH; Choe TB; Kim EK; Noh WC; Lee JK; Hong SI; Kim JI; Park IC
Cell Death Dis; 2012 Jun; 3(6):e319. PubMed ID: 22673193
[TBL] [Abstract][Full Text] [Related]
13. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
15. Fanconi anemia D2 protein is an apoptotic target mediated by caspases.
Park SJ; Beck BD; Saadatzadeh MR; Haneline LS; Clapp DW; Lee SH
J Cell Biochem; 2011 Sep; 112(9):2383-91. PubMed ID: 21520247
[TBL] [Abstract][Full Text] [Related]
16. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
17. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway.
Landais I; Sobeck A; Stone S; LaChapelle A; Hoatlin ME
Int J Cancer; 2009 Feb; 124(4):783-92. PubMed ID: 19048618
[TBL] [Abstract][Full Text] [Related]
18. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.
Landais I; Hiddingh S; McCarroll M; Yang C; Sun A; Turker MS; Snyder JP; Hoatlin ME
Mol Cancer; 2009 Dec; 8():133. PubMed ID: 20043851
[TBL] [Abstract][Full Text] [Related]
19. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
[TBL] [Abstract][Full Text] [Related]
20. High-risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de-ubiquitination of FancD2.
Khanal S; Galloway DA
PLoS Pathog; 2019 Feb; 15(2):e1007442. PubMed ID: 30818369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
